ÂÜÀòÂÒÂ×

Dr. Judy H. Chiao serves as a senior consultant for Vigeo Therapeutics bringing 20 years of experience in the clinical development of new oncology drugs. As a medical oncologist, she has designed and conducted clinical trials in advanced solid tumors and hematological malignancies in collaboration with leading disease experts at major medical centers in the U.S. and Europe. Previously, Dr. Chiao was Vice President of Clinical Development and Regulatory Affairs at Cyclacel Pharmaceuticals, Inc., where she led the clinical development of kinase inhibitors. Dr. Chiao began her industry career at Aton Pharma, Inc., a wholly-owned subsidiary of Merck & Co. Inc. Prior to Aton’s acquisition by Merck, she was responsible for leading the clinical development of Zolinza, an oral histone deacetylase inhibitor, for hematologic and solid tumor indications. In addition to her clinical development experience, Dr. Chiao brings regulatory expertise and insights after serving as Senior Medical Reviewer in the Division of Oncology Drug Products, Center for Drug Evaluation and Research, FDA.

Dr. Chiao received her M.D. from Harvard Medical School. She completed an internship and residency in internal medicine at Columbia-Presbyterian Medical Center. She held a Research Fellowship in Molecular Pharmacology at Sloan Kettering Institute for Cancer Research and a Clinical Fellowship in Hematology/Oncology at Memorial Sloan Kettering Cancer Center and has earned certifications in internal medicine and medical oncology. She holds a B.S in Chemistry from Columbia University.